Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
EQS continues to add functionality to its cloud-based offering, growing its potential share of client spend across investor relations, compliance and ...
Genkyotex is a Euronext-listed company formed by the merger of Genticel and Genkyotex focused on NOX science and its application in fibrosis and...
Novogen's recent market updates presented mixed news for investors. Recruitment in the Cantrixil Phase I is underway and preparations for the Phase...
SNP is acquiring BCC, one of the largest SAP partners in Central and Eastern Europe, for an undisclosed price. The deal broadens the group's customer ...
Hybrigenics' main focus is the development of inecalcitol as a niche treatment for leukaemia. In February it presented encouraging initial results...
Despite a strong run over the last 12 months, our increased valuation of $2.7bn suggests the market overlooks HCM's full R&D potential. Multiple...
FY16 earnings showed a good step forward without much help from markets. Acquisitions played a part in this as Epwin further built out its product...
As Marshall Motor (MMH) celebrates the second anniversary of its flotation on AIM, it can reflect positively on the continuation of its strong growth ...
We believe that factors are finally aligning to support adoption of Nanoco's quantum dots in the 250m+ unit per year TV and computer display markets. ...
Growth slowed in Q1, as the group focused its attention on delivering its strong backlog. Nevertheless, business remains healthy and management...
Oryzon has been making steady progress with its epigenetics R&D pipeline. Following positive Phase I/IIa trial results in December 2016, ORY-1001, an ...
National Grid's high visibility revenues, underwritten by regulatory returns across the UK and US, offer equity holders an attractive combination of...
We are initiating coverage on Arix Bioscience following its February 2017 IPO that raised £113m. Arix is a new transatlantic life sciences portfolio...
Liquefied Natural Gas Ltd (LNGL) has made progress in the last six months towards Final Investment Decision (FID). Signing binding tolling agreements ...
Positive data from the two Phase III trials in Lennox-Gastaut syndrome (LGS) patients, coupled with the previously announced positive Dravet syndrome ...
Quantum Genomics reported its yearly results, which highlighted the significant progress the company has made towards the commercialisation of its...
Immunovia has announced final top-line data of the IMMray platform from a retrospective study in autoimmune diseases. The study showed that the...
Prima BioMed has presented encouraging early signs of efficacy from the TACTI-mel trial of IMP321 in combination with Keytruda, with one of the six...
ReNeuron reported in December 2016 positive Phase II trial data for its CTX cells in chronic stroke patients, despite not meeting the three-month...
As the leading provider of data erasure software for the enterprise market, Blancco is well positioned to exploit the growing requirement for secure...
We expect forthcoming FY16 results (30 March) to highlight the strength of Polypipe's model with a strong y-o-y uplift in earnings and good cash...
For Thinfilm (THIN), 2016 has been principally dominated by a steadily growing list of new client partnerships, preparations for the move to the new...
Hutchison (HCM) and partner AstraZeneca presented positive preliminary data from the ongoing phase II proof-of-concept trial evaluating savolitinib...
TxCell's novel CAR-modified regulatory T-cell (CAR Treg) platform is developing well. CAR Tregs offer a powerful and versatile new approach to...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.